The estimated Net Worth of Adam Scott Levy is at least $24.8 Thousand dollars as of 13 February 2018. Mr. Levy owns over 9,090 units of Brickell Biotech Inc stock worth over $24,769 and over the last 8 years he sold BBI stock worth over $0. In addition, he makes $0 as Chief Business Officer at Brickell Biotech Inc.
Adam has made over 2 trades of the Brickell Biotech Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 9,090 units of BBI stock worth $49,995 on 13 February 2018.
The largest trade he's ever made was buying 9,090 units of Brickell Biotech Inc stock on 13 February 2018 worth over $49,995. On average, Adam trades about 1,032 units every 26 days since 2017. As of 13 February 2018 he still owns at least 10,540 units of Brickell Biotech Inc stock.
You can see the complete history of Mr. Levy stock trades at the bottom of the page.
Adam Scott Levy is Chief Business Officer of the Company. Mr. Levy has served as Brickell’s Chief Business Officer since 2019. Prior to joining Brickell, Mr. Levy served as Chief Business Officer at miRagen Therapeutics, a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need, from 2016 through 2019. Between 2000 through 2016, Mr. Levy held multiple Investment Banking positions at Merrill Lynch, Pierce, Fenner & Smith Incorporated, Jefferies Group and Wedbush Securities Inc. Mr. Levy received a B.S. in applied economics from Cornell University.
Adam Levy is 41, he's been the Chief Business Officer of Brickell Biotech Inc since 2019. There are 14 older and 3 younger executives at Brickell Biotech Inc. The oldest executive at Brickell Biotech Inc is Albert Nicholas Marchio II, 69, who is the Chief Financial Officer.
Adam's mailing address filed with the SEC is C/O BRICKELL BIOTECH, INC., 5777 CENTRAL AVENUE, SUITE 102, BOULDER, CO, 80301.
Over the last 5 years, insiders at Brickell Biotech Inc have traded over $0 worth of Brickell Biotech Inc stock and bought 584,350 units worth $353,337 . The most active insiders traders include Vijay B Samant, Monica E. Luchi, and Gary A Lyons. On average, Brickell Biotech Inc executives and independent directors trade stock every 16 days with the average trade being worth of $51,782. The most recent stock trade was executed by Reginald L Hardy on 23 July 2021, trading 200,000 units of BBI stock currently worth $134,000.
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell's executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell's strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs.
Brickell Biotech Inc executives and other stock owners filed with the SEC include: